A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors

Solid Tumor, Adult Clinical Trial

Official title:

A Phase I/II Trial of AK112 in Advanced Solid Tumor

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04597541
• Other study ID #: AK112-102
• Status: Active, not recruiting
• Phase: Phase 1/Phase 2
• Start date: October 21, 2020
• Est. completion date: May 2023

Study information

• Verified date: October 2022
• Source: Akeso
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. This trial is a two parts, phase I/II study. All patients are advanced solid tumor, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Part one is dose escalation phase,part two is dose expansion phase. The primary end point is safety. Secondary end points are objective response rate,progression-free survival and overall survival per RECIST1.1.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 59
• Est. completion date: May 2023
• Est. primary completion date: March 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Aged 18 to 75 years old (at the time consent is obtained);

• Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures);

• Have histologically- or cytologically-confirmed diagnosis of advanced solid tumor;

• Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy;

• Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or

• Subject must have at least one measurable lesion according to RECIST Version1.1;

• Adequate organ function;

• Females of childbearing potential and non-sterilized males who are sexually active must use an effective method;

• Adequate life expectancy.

Exclusion Criteria:

• History of severe hypersensitivity reactions to other mAbs;

• Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria;

• Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery;

• Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK112 except for treatment with small-molecule tyrosine kinase-targeted agents within 2 weeks prior to the first dose of AK112;

• History of primary immunodeficiency;

• Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis);

• History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives;

• Known allergy or reaction to any component of the AK112 formulation;

• History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies;

• Known history of tuberculosis;

• Known history of HIV;

• Receipt of live attenuated vaccination within 30 days prior to the first dose of AK112;

• Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor, Adult

Intervention

Drug:
• AK112
AK112 is a PD1/VEGF bispecific antibody;AK112 is given by intravenous infusion.

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Akeso

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events (AEs)	An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product.; temporally associated with the use of study treatment, whether or not considered related to the study treatment	From time ICF is signed until 90 days after last dose of AK112
Primary	Number of participants with DLTs	DLTs will be assessed during the first 4 weeks of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.	During the first four weeks of treatment
Secondary	Objective response rate (ORR)	The ORR is defined as the proportion of subjects with confirmed CR or confirmed PR, based on RECIST Version 1.1	Up to 2 years
Secondary	Disease control rate (DCR)	The DCR is defined as the proportion of subjects with CR, PR, or SD (subjects achieving SD will be included in the DCR if they maintain SD at 16 and 24 weeks respectively) based on RECIST Version 1.1.	Up to 2 years
Secondary	Progression-free survival (PFS)	Progression-free survival is defined as the time from the start of treatment with AK112 until the first documentation of disease progression or death due to any cause, whichever occurs first.	Up to 2 years
Secondary	Overall survival (OS)	Overall survival is defined as the time from the start of treatment with AK112 until death due to any cause.	Up to 2 years